Skip to content

Sleep Apnea-Hypopnea Syndrome and the Pathogenesis of Obesity

Sleep Apnea-Hypopnea Syndrome and the Pathogenesis of Obesity

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00456651
Enrollment
40
Registered
2007-04-05
Start date
2007-02-28
Completion date
Unknown
Last updated
2007-04-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, Sleep Apnea

Keywords

Sleep Apnea, Obesity, Neuropeptides, Hormones

Brief summary

The hypothesis of the study is the following: Patients with sleep apnea-hypopnea syndrome have different pattern in the secretion of hormones. The chronic sleep disorganization that suffer patients with sleep apnea-hypopnea syndrome (SAHS) may affect the central mechanisms that regulate nutritive behavior and energetic balance, causing an alteration in the secretion of hormones that favour the appearance and/or development of obesity.

Detailed description

OBJECTIVES: To compare the plasmatic profiles of different hormones and neuropeptides, related with weight control, metabolism and intake in patients with SAHS as well as in selected control subjects according to weight. DESIGN: Multicenter, prospective and controlled study. 40 patients with SAHS will be included as well as 40 control subjects. METHODS: To all subjects included in the study, the following procedures will be performed: 1. Medical History; 2. Anthropometric variables (height, weight, Body Mass Index; 3. Somnolence evaluation using the Epworth scale; 4. Conventional Polysomnography (PSG); 5. Determination every four hours during a 24 hours period of the levels of leptin adiponectin, resistin, insulin, PCR, etc. 6. Conventional biologic evaluation; 7. Patients will be re-evaluated after three months of treatment with CPAP.

Interventions

Sponsors

Fundacion Caubet-Cimera Islas Baleares
CollaboratorOTHER
Fondo de Investigacion Sanitaria
CollaboratorOTHER
Sociedad Española de Neumología y Cirugía Torácica
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
25 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Apnea-Hypopnea Index \> 15 * Body Mass Index \< 27 or \> 30 Kg/m2

Exclusion criteria

* Presence of any chronic disease * Drug addiction and/or alcoholism * Refusal to sign informed consent

Design outcomes

Primary

MeasureTime frame
OBJECTIVES: To compare the plasmatic profiles of different hormones
and neuropeptides, related with weight control, metabolism and intake
in patients with SAHS as well as in selected control subjects according
to weight.

Secondary

MeasureTime frame
CPAP (Continuous Positive Airway Pressure) effect on studied variables

Countries

Spain

Contacts

Primary ContactMónica de la Peña, MD
mdelapena@hsd.es34 971 175112

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026